Document is current
Any future updates will be listed below
-
Authors
Killarney, Shane T. http://orcid.org/0000-0002-8471-6641
Washart, Rachel http://orcid.org/0000-0001-6431-0188
Soderquist, Ryan S.
Hoj, Jacob P. http://orcid.org/0000-0003-3298-3083
Lebhar, Jamie
Lin, Kevin H.
Wood, Kris C. http://orcid.org/0000-0002-5887-2253
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA207083, R01CA263593)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 21 July 2022
Accepted: 3 March 2023
First Online: 14 March 2023
Competing interests
: K.C.W. is a founder, consultant, and equity holder at Tavros Therapeutics and Celldom and has performed consulting work for Guidepoint Global, Bantam Pharmaceuticals, and Apple Tree Partners. The remaining authors declare no competing interests.
